INNOVENT BIO: PROPOSED ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SECOND NEW DRUG APPLICATION FOR TALETRECTINIB (ROS1 INHIBITOR)
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE PHASE 3 CLINICAL STUDY OF IBI311 MET THE PRIMARY ENDPOINT IN TREATING THYROID EYE DISEASE
INNOVENT BIO: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
INNOVENT BIO: APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE FIRST NEW DRUG APPLICATION FOR MAZDUTIDE FOR CHRONIC WEIGHT MANAGEMENT
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
INNOVENT BIO: INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY''S PRODUCT REVENUE IN THE FOURTH QUARTER OF 2023
INNOVENT BIO: RETIREMENT OF CHIEF FINANCIAL OFFICER AND APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE FIRST PHASE 3 CLINICAL TRIAL OF MAZDUTIDE IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY MET THE PRIMARY AND ALL KEY SECONDARY ENDPOINTS
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE CHINA NATIONAL REIMBURSEMENT DRUG LIST (2023 VERSION) OF TYVYT''S SEVENTH INDICATION AND BYVASDA''S EIGHTH INDICATION
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED AND GRANTED PRIORITY REVIEW DESIGNATION TO THE NEW DRUG APPLICATION FOR IBI-351 (KRAS G12C INHIBITOR)
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR TALETRECTINIB (ROS1 INHIBITOR)
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES OLVEREMBATINIB FOR THE TREATMENT OF CML-CP PATIENTS WHO ARE RESISTANT AND/OR INTOLERANT TO 1st AND 2nd GENERATION TKI TREATMENT
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
INNOVENT BIO: INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY''S PRODUCT REVENUE IN THE THIRD QUARTER OF 2023
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
No Data